Colitis, Ulcerative
Conditions
Keywords
Telemedicine
Brief summary
This study is designed to assess differences in remote and on-site patient study participation in the State of Massachusetts, as well as the significance of dietary interventions and their impact on UC. The study will activate one site with a Principal Investigator who will utilize each subject's local care system (local Gastroenterologist) to collect study data, along with telemonitoring and video visits, to make key study assessments and decisions regarding subjects' progression in the study.
Interventions
BEHAVIORALCombined Anti-inflammatory Diet (CAID)
The CAID requires participants to modify their diet to include certain types of foods that may have anti-inflammatory properties. Participants on the CAID will be required to abstain from red meat and alcoholic beverages.
Sponsors
Transparency Life Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
HEALTH_SERVICES_RESEARCH
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 80 Years
Healthy volunteers
No
Inclusion criteria
1. Males and females between the ages of 18 and 80, inclusive, who reside in the state of Massachusetts. 2. Ability and willingness to provide documented informed consent and to comply with the study procedures, including in-person visits for Arm 1 and video visits for Arm 2. 3. Documented history of moderate to severe active UC 4. Disease duration of ≥12 weeks at the time of screening (diagnosed according to American College of Gastroenterology practice guidelines) 5. Screening fecal calprotectin\>350 mg/g 6. Diagnosis of moderately to severely active UC, including historical endoscopy sub score ≥2; a rectal bleeding sub score ≥1 and disease activity a minimum of 25 cm from the anal verge. 7. Documented (via video or report) endoscopy performed within 2 years prior to randomization. 8. Access to a computer or mobile device with internet connection and an active email address.
Exclusion criteria
1. Prior extensive colonic resection, subtotal or total colectomy or planned surgery for UC 2. Past or present ileostomy or colostomy 3. Short bowel syndrome 4. Diagnosis of indeterminate colitis, fulminant colitis, toxic megacolon 5. Past or present fistula or abdominal abscess 6. History or current evidence of colonic mucosal dysplasia 7. Use of tube feeding, defined formula diets or parenteral alimentation/nutrition which has not been discontinued ≥3 weeks prior to study enrollment 8. Use of anticoagulants, herbal supplements and omega-3/fish oil supplements during the study 9. Crohn's Disease 10. Significant uncontrolled co-morbidity, such as neurological, cardiac (e.g., moderate to severe heart failure NYHA class III/IV), pulmonary, renal, hepatic, endocrine or gastrointestinal disorders 11. History of alcohol, drug or chemical abuse within 6 months prior to screening 12. Pregnant females, those intending to become pregnant, and those who are lactating 13. Current participation in any other clinical trial
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Endoscopy Mayo Score Comparison (proportion of endoscopies to which an independent reader can successfully assign an endoscopic Mayo Clinic sub-score) | Week 1 | Comparison of the proportion of endoscopies to which an independent reader can successfully assign an endoscopic Mayo Clinic sub-score between Study Arms 1 and 2. |
| Compliance (proportion of missing or non-evaluable records per patient and the proportion of patients who did not complete the study) | Week 7 | Comparison of the proportion of missing or non-evaluable records per patient and the proportion of patients who did not complete the study between Study Arms 1 and 2. |
| Combined Anti-inflammatory Diet (Change from baseline in fecal calprotectin/microbiome levels) | Weeks 0, 5 and 7 | Change from baseline in fecal calprotectin/microbiome levels between Control (standard nutritional advice) and CAID (dietary intervention) arms. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Participant Satisfaction Survey | Week 7 | Difference in reported patient satisfaction with trial participation between arms 1 and 2. |
| Mayo Score and Patient Simple Clinical Colitis Activity Index Difference (Difference in partial Mayo Clinic sub-Score and Patient Simple Clinical Colitis Activity Index) | Weeks 1 and 7 | Difference in partial Mayo Clinic sub-Score and Patient Simple Clinical Colitis Activity Index between Control and CAID (dietary intervention). |
| Physician's Global Assessment Discrepancy Frequency | Week 7 | Frequency of discrepancy between Principal Investigator-assessed and gastroenterologist-assessed Mayo Clinic Physician's Global Assessment Sub-Score for Arm 2 patients at baseline. |
| Mayo Score Discrepancy Frequency | Week 7 | Frequency of discrepancy between Principal Investigator-assessed and gastroenterologist-assessed Mayo Clinic Endoscopy Sub-Scores for Arm 2 patients at baseline. |
| Adverse Events | Weekly through week 11 | Difference in incidence of Adverse Events (AEs) and Serious Adverse Events (SAEs) between Study Arms 1 and 2 and between Control and CAID (dietary intervention) arms. |
| Dietary Compliance Comparison | Week 7 | Comparison of patient non-compliance events with dietary regimen between arms 1 and 2. |
Countries
United States
Contacts
Primary ContactJustine States
Outcome results
None listed